Patents Assigned to Respivert Limited
-
Patent number: 11208381Abstract: The present invention relates inter alia to a compound of formula (I) wherein R1, R2 and R3, are as defined in the specification and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of fibrotic diseases or interstitial lung diseases, in particular idiopathic pulmonary fibrosis.Type: GrantFiled: June 1, 2020Date of Patent: December 28, 2021Assignee: RESPIVERT LIMITEDInventors: Iain Walters, Louise Birch, Stephen Paul Collingwood, Christopher Scott Stevenson
-
Patent number: 11142515Abstract: There are provided compounds of formula (I) as defined in the specification which are p38 MAP kinase inhibitors for use as medicaments for the treatment inter alia of inflammatory diseases.Type: GrantFiled: March 27, 2019Date of Patent: October 12, 2021Assignee: Respivert LimitedInventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Diane Venable, Iain Walters
-
Patent number: 11046672Abstract: The present invention relates inter alia to a compound of formula (I) Wherein R1, R2, R3 and Z are as defined in the specification and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of fibrotic diseases or interstitial lung diseases, in particular idiopathic pulmonary fibrosis.Type: GrantFiled: December 23, 2016Date of Patent: June 29, 2021Assignee: RespiVert LimitedInventors: Iain Walters, Louise Birch, Joseph Hill-Cousins, Stephen Paul Collingwood, Christopher Scott Stevenson
-
1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors
Patent number: 10813932Abstract: There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.Type: GrantFiled: February 26, 2019Date of Patent: October 27, 2020Assignee: Respivert LimitedInventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw -
1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-i-yl) ureas as P38 mapkinase inhibitors
Patent number: 10738032Abstract: There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.Type: GrantFiled: February 26, 2019Date of Patent: August 11, 2020Assignee: Respivert LimitedInventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw, Rudy Broeckx, Walter Filliers, Alex Copmans -
Patent number: 10669235Abstract: The present invention relates inter alia to a compound of formula (I) wherein R1, R2 and R3, are as defined in the specification and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of fibrotic diseases or interstitial lung diseases, in particular idiopathic pulmonary fibrosis.Type: GrantFiled: March 8, 2017Date of Patent: June 2, 2020Assignee: RESPIVERT LIMITEDInventors: Iain Walters, Louise Birch, Stephen Paul Collingwood, Christopher Scott Stevenson
-
Patent number: 10294216Abstract: There are provided compounds of formula (I) shown below as defined in the specification which are p38 MAP kinase inhibitors for use as medicaments for the treatment inter alia of inflammatory diseases.Type: GrantFiled: December 21, 2017Date of Patent: May 21, 2019Assignee: RESPIVERT LIMITEDInventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Diane Venable, Iain Walters
-
1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors
Patent number: 10266519Abstract: There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.Type: GrantFiled: November 14, 2017Date of Patent: April 23, 2019Assignee: RESPIVERT LIMITEDInventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw, Rudy Broeckx, Walter Filliers, Alex Copmans -
Patent number: 10238658Abstract: There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.Type: GrantFiled: March 19, 2018Date of Patent: March 26, 2019Assignee: RESPIVERT LIMITEDInventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw
-
Patent number: 10072034Abstract: There are provided compounds of formula I, wherein T, A, Q, Z, G, R4, R5a, R5b and n have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: April 6, 2017Date of Patent: September 11, 2018Assignees: Respivert Limited, Topivert Pharma LimitedInventors: Matthew Colin Thor Fyfe, Stephen Malcolm Thom
-
Patent number: 10000471Abstract: There are provided inter alia compounds of formula (I) wherein R1, R2a, R2b, R3, R4, L, X, R5 and R6 are as defined in the description for use in the treatment of inflammatory diseases.Type: GrantFiled: August 29, 2017Date of Patent: June 19, 2018Assignee: Respivert LimitedInventors: John King-Underwood, George Hardy, Peter John Murray, Jonathan Gareth Williams, Stuart Thomas Onions
-
Patent number: 9890185Abstract: There are provided compounds of formula I, wherein R1, R1A, R1C to R1E, Ra, Rb, X1, E and G have meanings given in the description, which compounds have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: December 19, 2014Date of Patent: February 13, 2018Assignees: Respivert Limited, Topivert Pharma LimitedInventors: Matthew Colin Thor Fyfe, Stephen Malcolm Thom, Thomas Matthew Baker, Gareth William Harbottle, Vedran Hasimbegovic, Aaron Rigby
-
Patent number: 9884845Abstract: There are provided compounds of formula (I) as defined in the specification, which are p38 MAP kinase inhibitors for use as medicaments for the treatment inter alia of inflammatory diseases.Type: GrantFiled: February 13, 2015Date of Patent: February 6, 2018Assignee: Respivert LimitedInventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Diane Venable, Iain Walters
-
Publication number: 20180000830Abstract: The present invention relates inter alia to the treatment or prevention of influenza virus infection (including subtypes influenza A virus, influenza B virus, avian strain H5N1, A/H1N1, H3N2 and/or pandemic influenza) using compounds which inhibit the activity of p59-HCK and to a method of screening for a candidate drug substance intended to prevent or treat influenza virus infection in a subject, said method comprising identifying a test substance capable of inhibiting p59-HCK activity.Type: ApplicationFiled: September 15, 2017Publication date: January 4, 2018Applicant: Respivert LimitedInventors: Catherine Elisabeth Charron, Robert Fenton, Scott Crowe, Kazuhiro Ito, Peter Strong, William Garth Rapeport, Keith Ray
-
Patent number: 9850233Abstract: There are provided compounds of formula I, wherein: Y represents NR2R3; one of R2 and R3 represents —[C2-4 alkylene-O]1-12—[C2-4 alkylene]-R2a and the other of R2 and R3 has a meaning given in the description; and R, R1, R2a, Ra, Rb, Q, X and Y have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: July 12, 2016Date of Patent: December 26, 2017Assignees: Respivert Limited, Topivert Pharma LimitedInventor: Matthew Colin Thor Fyfe
-
1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors
Patent number: 9850231Abstract: There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.Type: GrantFiled: July 10, 2015Date of Patent: December 26, 2017Assignee: Respivert LimitedInventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw, Rudy Broeckx, Walter Filliers, Alex Copmans -
Publication number: 20170362208Abstract: There are provided inter alia compounds of formula (I) wherein R1, R2a, R2b, R3, R4, L, X, R5 and R6 are as defined in the description for use in the treatment of inflammatory diseases.Type: ApplicationFiled: August 29, 2017Publication date: December 21, 2017Applicant: Respivert LimitedInventors: John King-Underwood, George Hardy, Peter John Murray, Jonathan Gareth Williams, Stuart Thomas Onions
-
Patent number: 9822076Abstract: There is provided a compound of formula VIIa, wherein Qx represents —C(O)O—C1-4 alkyl, or a salt or protected derivative thereof, and other compounds that are useful in the preparation of compounds that have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and has use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: October 12, 2016Date of Patent: November 21, 2017Assignees: Respivert Limited, Topivert Pharma LimitedInventor: Matthew Colin Thor Fyfe
-
Patent number: 9796742Abstract: There are provided compounds of formula I, wherein R1 to R5, X1, X2, Ar, L, A, A1, E and G have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: August 4, 2016Date of Patent: October 24, 2017Assignees: Respivert Limited, Topivert Pharma LimitedInventors: Matthew Colin Thor Fyfe, Michael Knaggs, Premji Meghani, Stephen Malcolm Thom
-
Patent number: 9790209Abstract: There are provided compounds of formula I, wherein R1 to R5, X1, X2, Ar, L, E, A, A1, G and G1 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: August 1, 2016Date of Patent: October 17, 2017Assignees: Respivert Limited, Topivert Pharma LimitedInventors: Matthew Colin Thor Fyfe, Premji Meghani, Matthew Alexander Henry Stent, Stephen Malcolm Thom, Claire Anne Walshe